Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients
from Journal for Immunotherapy of Cancer
Checkpoint inhibitors have revolutionized the treatment of cancer, but their use remains limited by off-target inflammatory and immune-related adverse events. Solid organ transplantation recipients have been excluded from clinical trials owing to concerns about alloimmunity, organ rejection, and immunosuppressive therapy. Thus, scientists conducted a retrospective study and literature review to evaluate the safety of CPIs in patients with cancer and prior SOT.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063